Prognostic value of brain natriuretic peptide in patients with heart failure and reserved left ventricular systolic function

Gong,Hui; Wang,Xin; Ling,Yi; Shi,Yijun; Shi,Haiming

doi:10.3892/etm.2014.1635

Prognostic value of brain natriuretic peptide in patients with heart failure and reserved left ventricular systolic function

Authors:
- Hui Gong
- Xin Wang
- Yi Ling
- Yijun Shi
- Haiming Shi
View Affiliations

Affiliations: Division of Cardiology, Department of Medicine, Huashan Hospital of Fudan University, Shanghai 200040, P.R. China, Division of Cardiology, Department of Medicine, Jinshan Hospital of Fudan University, Shanghai 201508, P.R. China
Published online on: March 27, 2014 https://doi.org/10.3892/etm.2014.1635
Pages: 1506-1512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Brain natriuretic peptide (BNP) is used as a prognostic biomarker for patients with heart failure (HF) in clinical practice, however, the correlation between BNP levels and the prognosis of HF in patients with reserved left ventricular systolic function (RLVSF) is not clear. Thus, the aim of the present study was to evaluate the added value of BNP in the prognosis of HF patients with RLVSF. Inpatients with cardiovascular disease (mean age, 65.7 years; male, 790; female, 625) admitted to the Division of Cardiology at Jinshan Hospital of Fudan University (Shanghai, China) between June 2006 and December 2009 underwent follow‑up examinations. Plasma BNP levels were analyzed and measurements of the left ventricular ejection fraction (LVEF) were performed by echocardiography. Evaluations of the patients with HF were performed according to the New York Heart Association (NYHA) classification system. The duration of the follow‑up period ranged between 21 and 63 months (average duration, 35.8 months) and key events included cardiovascular mortality, readmission due to cardiovascular disease or mortality due to other reasons. Survival times decreased with increasing BNP levels in all the follow‑up patients (Spearman's ρ, ‑0.1877; P<0.0001). Among the 1,415 patients, 1,312 underwent echocardiographic detection. A total of 395 patients with NYHA classes II‑IV and a LVEF ≥45% were selected. The incidence of compound endpoint events was significantly higher in the patients that had BNP levels of >100 pg/ml when compared with the patients that had BNP levels of ≤100 pg/ml (37.07 vs. 23.93%; relative risk, 1.55); consequently the survival times were significantly reduced (P=0.0039). A negative correlation was identified between the BNP levels and the survival times in these patients (Spearman's ρ, ‑0.1738; P=0.0005). These results indicated that the levels of BNP may be used to predict the prognosis of patients with cardiovascular disease. The prognoses of patients with higher BNP levels were worse compared with the patients with lower BNP levels. Furthermore, significant correlations were confirmed in the HF patients with RLVSF.

View Figures

View References

1	Epshteyn V, Morrison K, Krishnaswamy P, et al: Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 26:2081–2087. 2003. View Article : Google Scholar : PubMed/NCBI
2	Magnusson M, Melander O, Israelsson B, et al: Elevated plasma levels of NT-proBNP in patients without overt cardiovascular disease. Diabetes Care. 27:1929–1935. 2004. View Article : Google Scholar : PubMed/NCBI
3	Kremastinos DT, Tsiapras DP, Kostopoulou AG, et al: NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients. Eur J Heart Fail. 9:531–536. 2007. View Article : Google Scholar : PubMed/NCBI
4	Sakata K, Iida K, Mochiduki N and Nakaya Y: Brain natriuretic peptide (BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic ischemic heart failure. Intern Med. 48:393–400. 2009. View Article : Google Scholar
5	McKie PM, Rodeheffer RJ, Cataliotti A, et al: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 47:874–880. 2006. View Article : Google Scholar : PubMed/NCBI
6	Krittayaphong R, Boonyasirinant T, Saiviroonporn P, et al: Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J Card Fail. 14:687–694. 2008. View Article : Google Scholar
7	Karaca II, Gülcü E, Yavuzkir M, et al: B-type natriuretic peptide level in the diagnosis of asymptomatic diastolic dysfunction. Anadolu Kardiyol Derg. 7:262–267. 2007.PubMed/NCBI
8	Kremastinos DT, Hamodraka E, Parissis J, et al: Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. Am Heart J. 159:68–74. 2010. View Article : Google Scholar : PubMed/NCBI
9	Panou FK, Kotseroglou VK, Lakoumentas JA, et al: Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Hellenic J Cardiol. 47:344–351. 2006.PubMed/NCBI
10	Eroglu S, Yildirir A, Bozbas H, et al: Brain natriuretic peptide levels and cardiac functional capacity in patients with dyspnea and isolated diastolic dysfunction. Int Heart J. 48:97–106. 2007. View Article : Google Scholar : PubMed/NCBI
11	Romano S, di Mauro M, Fratini S, et al: Serial BNP assay in monitoring exercise tolerance in patients with diastolic dysfunction. Int J Cardiol. 147:312–313. 2011. View Article : Google Scholar : PubMed/NCBI
12	Hunt SA, Abraham WT, Chin MH, et al: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 112:e154–e235. 2005.
13	Teicholz LE, Kreulen T, Herman MV and Gorlin R: Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 37:7–11. 1976.
14	Speranza L, Franceschelli S, Riccioni G, et al: BNP and iNOS in decompensated chronic heart failure: a linear correlation. Front Biosci (Elite Ed). 4:1255–1262. 2012. View Article : Google Scholar : PubMed/NCBI
15	He Q, Wu G and Lapointe MC: Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac. Am J Physiol Endocrinol Metab. 278:E1115–E1123. 2000.PubMed/NCBI
16	Suo M, Hautala N, Földes G, et al: Posttranscriptional control of BNP gene expression in angiotensin II-induced hypertension. Hypertension. 39:803–808. 2002. View Article : Google Scholar : PubMed/NCBI
17	James SK, Lindahl B, Siegbahn A, et al: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 108:275–281. 2003.
18	Morrow DA, de Lemos JA, Blazing MA, et al; Investigators. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 294:2866–2871. 2005. View Article : Google Scholar : PubMed/NCBI
19	Morrow DA, de Lemos JA, Sabatine MS, et al: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 41:1264–1272. 2003. View Article : Google Scholar : PubMed/NCBI
20	Ceriani L and Giovanella L: Cardiac natriuretic peptides after myocardial infarction: relationship with infarct size, left ventricular function and remodelling assessed by 99mTc-sestamibi gated-single photon emission tomography. Clin Chem Lab Med. 45:226–231. 2007. View Article : Google Scholar
21	Kragelund C, Grønning B, Køber L, et al: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 352:666–675. 2005. View Article : Google Scholar : PubMed/NCBI
22	Barbosa MM, Nunes Mdo C, Castro LR, et al: Correlation between NT-pro BNP levels and early mitral annulus velocity (E′) in patients with non-ST-segment elevation acute coronary syndrome. Echocardiography. 25:353–359. 2008.PubMed/NCBI
23	Casco VH, Veinot JP, Kuroski de Bold ML, et al: Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem. 50:799–809. 2002. View Article : Google Scholar : PubMed/NCBI
24	Weber M, Dill T, Arnold R, et al: N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J. 148:612–620. 2004. View Article : Google Scholar : PubMed/NCBI
25	Omland T: B-type natriuretic peptides: prognostic markers in stable coronary artery disease. Expert Rev Mol Diagn. 8:217–225. 2008. View Article : Google Scholar : PubMed/NCBI
26	Goetze JP, Christoffersen C, Perko M, et al: Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 17:1105–1107. 2003.PubMed/NCBI
27	Goetze JP, Gore A, Møller CH, et al: Acute myocardial hypoxia increases BNP gene expression. FASEB J. 18:1928–1930. 2004.PubMed/NCBI
28	Omland T, Persson A, Ng L, et al: N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 106:2913–2918. 2002. View Article : Google Scholar : PubMed/NCBI
29	de Lemos JA, Morrow DA, Bentley JH, et al: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 345:1014–1021. 2001.
30	Kragelund C, Gustafsson I, Omland T, et al: Prognostic value of NH₂-terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care. 29:1411–1413. 2006.
31	Kelder JC, Rutten FH and Hoes AW: Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure. Fam Pract. 26:69–74. 2009. View Article : Google Scholar : PubMed/NCBI
32	Redfield MM, Jacobsen SJ, Burnett JC Jr, et al: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 289:194–202. 2003. View Article : Google Scholar : PubMed/NCBI
33	Shimabukuro M, Higa N, Oshiro Y, et al: Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients. Diabetes Obes Metab. 9:323–329. 2007. View Article : Google Scholar : PubMed/NCBI
34	Görmüş U, Ozmen D, Ozmen B, et al: Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. Diabetes Res Clin Pract. 87:51–56. 2010.PubMed/NCBI
35	Metra M, Ponikowski P, Dickstein K, et al; Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 9:684–694. 2007. View Article : Google Scholar : PubMed/NCBI
36	Nagueh SF, Appleton CP, Gillebert TC, et al: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 22:107–133. 2009. View Article : Google Scholar : PubMed/NCBI
37	Grewal J, McKelvie R, Lonn E, et al: BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail. 10:252–259. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kotaska K, Popelova J, Tiserova M, et al: NT-proBNP and BNP values in cardiac patients with different degree of left ventricular systolic dysfunction. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 150:125–130. 2006. View Article : Google Scholar : PubMed/NCBI
39	Mair J, Hammerer-Lercher A and Puschendorf B: The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med. 39:571–588. 2001. View Article : Google Scholar : PubMed/NCBI
40	Ruskoaho H: Cardiac hormones as diagnostic tools in heart failure. Endor Rev. 24:341–356. 2003. View Article : Google Scholar : PubMed/NCBI
41	Ray P, Arthaud M, Birolleau S, et al: Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc. 53:643–648. 2005. View Article : Google Scholar : PubMed/NCBI
42	Sykes E, Karcher RE, Eisenstadt J, et al: Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP. Am J Clin Pathol. 123:584–590. 2005. View Article : Google Scholar : PubMed/NCBI
43	Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 4(Suppl 7): S21–S30. 2003.
44	Vickery S, Price CP, John RI, et al: B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 46:610–620. 2005. View Article : Google Scholar : PubMed/NCBI
45	Richards AM, Nicholls MG, Espiner EA, et al: B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 107:2786–2792. 2003. View Article : Google Scholar : PubMed/NCBI